Atorvastatin-induced diaphragmatic muscle impairment [3]

Annals of Pharmacotherapy

Volumn 35, Issue 10, 2001, Pages 1292-1293

  Sulem, P ^a   Bagheri, H ^a   Faixo, Y ^a   Montastruc, J L ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; CASE REPORT; CLINICAL EXAMINATION; CREATINE KINASE BLOOD LEVEL; DIAPHRAGM MUSCLE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; MALE; MUSCLE DISEASE; MYALGIA; PATHOGENESIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR;

EID: 0034793577     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10366     Document Type: Letter

References (5)

1. HMG-CoA reductase inhibitors and myotoxicity
2. A method for estimating the probability of adverse drug reactions
3. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
4. Adverse effect of drugs on the respiratory muscles
5. HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats